RC
VIRX

RegentAtlantic Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

RegentAtlantic Capital’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-11
Closed -$5.78K – 990
2014
Q4 		$5.78K Buy
+11
New +$4.96K ﹤0.01% 993

Other funds holding VIRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RegentAtlantic Capital's VIRX Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2015, closing a stake of 11 shares — an estimated $5.78K sold.

RegentAtlantic Capital first reported a position in VIRX in Q4 2014 and held it in 1 quarter. The position peaked at $5.78K in Q4 2014. 83 funds tracked by Wall St. Rank hold VIRX as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 11 Viracta Therapeutics, Inc. Common Stock shares in Q1 2015, an estimated $5.78K.
  • RegentAtlantic Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $5.78K in Q4 2014.
  • 83 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.